Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 15/20 | 0.62 |
| ▸ | SLC9A5 | Q14940 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460538 | 1.00 | PLAU (0.62) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| N,N-Hexamethyleneamiloride SCHEMBL7862943 | 1.00 | PLAU (0.62) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL11469206 | 0.99 | PLAU (0.60) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL26104614 | 0.88 | ALDH1A1 (0.47) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL11615921 | 0.85 | PLAU (0.53) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL15082596 | 0.84 | PLAU (0.57) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| Amiloride SCHEMBL365969 | 0.82 | SCNN1A (0.55) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL17704667 | 0.82 | PLAU (0.62) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL11467427 | 0.80 | GRM5 (0.48) | PLAUSLC9A5LMNANPC1ALDH1A1 | |
| SCHEMBL26106945 | 0.80 | GRM5 (0.58) | PLAUSLC9A5LMNANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| CN-117323334-A | Application of NHE1 inhibitor in preparation of medicine for preventing and treating multiple myeloma | 暨南大学 | 2024-01-02 | — | — | CN | claimed |
| CN-114712361-A | Compositions and methods for preventing or reducing the incidence of transient ischemic attacks | 莫尔豪斯医学院 | 2022-07-08 | — | — | CN | claimed |
| CN-109475552-B | Methods and compositions for appetite control and weight management | 上海药苑生物科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4536354-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-110742891-B | Composition for reducing damage to nervous system, method for producing the same, and use of the same | 莫尔豪斯医学院 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| CN-117323334-A | Application of NHE1 inhibitor in preparation of medicine for preventing and treating multiple myeloma | 暨南大学 | 2024-01-02 | — | — | CN | disclosed |
| CN-117243839-A | Minoxidil adjuvant therapy | 应用生物学股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114712361-A | Compositions and methods for preventing or reducing the incidence of transient ischemic attacks | 莫尔豪斯医学院 | 2022-07-08 | — | — | CN | disclosed |
| CN-109475552-B | Methods and compositions for appetite control and weight management | 上海药苑生物科技有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20220040225-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-02-10 | — | — | US | disclosed |